LGDN Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Ligand Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 164 EUR Market Closed

Market Cap: €2.9B

L	Ligand Pharmaceuticals Inc XBER:LGDN	US
C	Consti Oyj OMXH:CONSTI	FI
	HIAG Immobilien Holding AG F:0HG	CH
F	Fraport Frankfurt Airport Services Worldwide AG DUS:FRA	DE
	Murray & Roberts Holdings Ltd F:LDYA	ZA
	Panthera Resources PLC OTC:PATRF	UK
	HB Fuller Co NYSE:FUL	US
S	Suzuki Motor Corp DUS:SUK	JP
A	Asure Software Inc XBER:VTE1	US
C	Chevron Corp XHAM:CHV	US
R	Royal Dutch Shell PLC OTC:RYDAF	NL
C	Costco Wholesale Corp BMV:COST	US
	Isetan Mitsukoshi Holdings Ltd TSE:3099	JP
	Amadeus IT Group SA F:AI3A	ES
	Citigroup Inc NYSE:C	US

Profitability Summary

Ligand Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

95%

Strong 3Y Average Gross Margin

90%

Gross Margin is Increasing

72% > 95%

Healthy Operating Margin

18%

Low 3Y Average Operating Margin

Declining Operating Margin

20% > 18%

Exceptional Net Margin

46%

Sustainable 3Y Average Net Margin

15%

Net Margin is Increasing

13% > 46%

Exceptional Free Cash Flow Margin

18%

Strong 3Y Average Free Cash Flow Margin

22%

Declining Free Cash Flow Margin

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.